1. Home
  2. IMUX vs UBXG Comparison

IMUX vs UBXG Comparison

Compare IMUX & UBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • UBXG
  • Stock Information
  • Founded
  • IMUX 2016
  • UBXG 2018
  • Country
  • IMUX United States
  • UBXG China
  • Employees
  • IMUX N/A
  • UBXG N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • UBXG
  • Sector
  • IMUX Health Care
  • UBXG
  • Exchange
  • IMUX Nasdaq
  • UBXG Nasdaq
  • Market Cap
  • IMUX 67.8M
  • UBXG 67.8M
  • IPO Year
  • IMUX N/A
  • UBXG 2024
  • Fundamental
  • Price
  • IMUX $0.96
  • UBXG $3.09
  • Analyst Decision
  • IMUX Strong Buy
  • UBXG
  • Analyst Count
  • IMUX 5
  • UBXG 0
  • Target Price
  • IMUX $7.50
  • UBXG N/A
  • AVG Volume (30 Days)
  • IMUX 1.1M
  • UBXG 14.2K
  • Earning Date
  • IMUX 08-11-2025
  • UBXG 01-01-0001
  • Dividend Yield
  • IMUX N/A
  • UBXG N/A
  • EPS Growth
  • IMUX N/A
  • UBXG N/A
  • EPS
  • IMUX N/A
  • UBXG N/A
  • Revenue
  • IMUX N/A
  • UBXG $39,603,353.00
  • Revenue This Year
  • IMUX N/A
  • UBXG N/A
  • Revenue Next Year
  • IMUX N/A
  • UBXG N/A
  • P/E Ratio
  • IMUX N/A
  • UBXG N/A
  • Revenue Growth
  • IMUX N/A
  • UBXG N/A
  • 52 Week Low
  • IMUX $0.56
  • UBXG $2.36
  • 52 Week High
  • IMUX $2.11
  • UBXG $567.04
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 55.60
  • UBXG N/A
  • Support Level
  • IMUX $0.94
  • UBXG N/A
  • Resistance Level
  • IMUX $1.18
  • UBXG N/A
  • Average True Range (ATR)
  • IMUX 0.08
  • UBXG 0.00
  • MACD
  • IMUX 0.01
  • UBXG 0.00
  • Stochastic Oscillator
  • IMUX 40.95
  • UBXG 0.00

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About UBXG U-BX Technology Ltd. Ordinary Shares

U-BX Technology Ltd is focused on providing value-added services using artificial intelligence-driven technology to businesses within the insurance industry, including insurance carriers and brokers. It helps institutional clients obtain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or its clients' promotion time through those channels. The company derives a majority of its revenue by providing digital promotion services to its clients and also engages in providing risk assessment services, and value-added bundled benefits. It has developed an algorithm named Magic Mirror, to calculate payout risks for insurance carriers to underwrite auto insurance coverage. Geographically, all of the company's revenue is derived from Mainland China.

Share on Social Networks: